Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Deferred Taxes (2021 - 2023)

Oncology Institute (TOI) has disclosed Deferred Taxes for 3 consecutive years, with -$126000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Deferred Taxes rose 71.75% year-over-year to -$126000.0, compared with a TTM value of -$126000.0 through Sep 2024, up 68.18%, and an annual FY2023 reading of -$76000.0, up 71.1% over the prior year.
  • Deferred Taxes was -$126000.0 for Q4 2023 at Oncology Institute, down from $80000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $2.3 million in Q4 2021 and bottomed at -$3.8 million in Q3 2021.
  • Average Deferred Taxes over 3 years is -$143727.3, with a median of -$4000.0 recorded in 2023.
  • Peak annual rise in Deferred Taxes hit 101.38% in 2022, while the deepest fall reached 119.43% in 2022.
  • Year by year, Deferred Taxes stood at $2.3 million in 2021, then crashed by 119.43% to -$446000.0 in 2022, then soared by 71.75% to -$126000.0 in 2023.
  • Business Quant data shows Deferred Taxes for TOI at -$126000.0 in Q4 2023, $80000.0 in Q3 2023, and -$4000.0 in Q2 2023.